We next investigated the response of the CD138+ plasma cell samples from 35 patients, to five anti-myeloma therapies: Bortezomib (PI), Lenolidomide (IMiD), Navitoclax (BCL-2 inhibitor), Quizinostat (HDACi) and the investigational drug PF-04691502. This evidence concerns the gene BCL2 and plasma cell myeloma.